SynAct Pharma prepares phase III trial discussion with FDA
SynAct Pharma presented post-hoc analysis of its phase IIb ADVANCE rheumatoid arthritis study using resomelagon, addressing placebo responses and reinforcing its therapeutic profile. The company is preparing to discuss phase III trial design with the FDA.
SynAct Pharma has presented a post-hoc analysis of the phase IIb ADVANCE study of resomelagon in rheumatoid arthritis. The company said the new data clarify previous placebo responses and reinforce the drug’s therapeutic profile. SynAct Pharma is now preparing to discuss the design of a phase III trial with the FDA.